> No clinical efficacy, safety, pharmacology, non-clinical or manufacturing issues were raised and noadditional clinical studies are required by FDA to support NDA approval
Pretty happy with that all things considered.
Ann: FDA Letter Requires Patient Instruction Update, page-15
-
- There are more pages in this discussion • 281 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
-0.010(2.63%) |
Mkt cap ! $669.7M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 37.5¢ | 36.0¢ | $2.791M | 7.575M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 466364 | 36.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 195311 | 4 |
View Market Depth
| Last trade - 15.50pm 19/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |